CIPO2015: Pre-clinical and Clinical Development of CD22-Targeted CAR T Cells

preview_player
Показать описание
Dr. Terry Fry of the National Cancer Institute speaks about adoptive cell therapies for pediatric cancers at the 4th International Conference on Immunotherapy in Pediatric Oncology (CIPO2015), hosted by Seattle Children’s Research Institute. Specifically, Dr. Fry provides an overview of the preclinical development of CD22 CAR and shows clinical trial data from the CD22 CAR trial.

Terry Fry, MD, Head, Hematologic Malignancies Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health

09/26/2015

  1. UW Video
  2. UW
  3. University of Washington
  4. ALL
  5. acute lymphoblastic leukemia
  6. CD22 CAR
Рекомендации по теме
CIPO2015: Pre-clinical and 0:16:28

CIPO2015: Pre-clinical and Clinical Development of CD22-Targeted CAR T Cells

CIPO2015: Dual Targeting 0:11:22

CIPO2015: Dual Targeting of CD19 & CD22 on B-ALL Using a Single Bispecific Chimeric Antigen Rece...

CIPO2015: T Cells 0:28:28

CIPO2015: T Cells as Biotherapeutics for Solid Tumors

CIPO2015: Adoptive T 0:15:02

CIPO2015: Adoptive T Cell Immunotherapy Targeting the Minor Histocompatibility Antigen HA-1

The Complexities of 1:01:14

The Complexities of the CAR T Cell: Implications for Clinical Trial Designs

Taking CAR T 0:22:25

Taking CAR T Therapy for a Preclinical Test Drive

Preclinical Evaluation of 0:48:20

Preclinical Evaluation of CAR T Immunotherapies Using Novel Animal Models [Webinar]

CIPO2015: Optimizing Adoptive 0:27:33

CIPO2015: Optimizing Adoptive Immunotherapy for Cancer

CIPO2015: Durable Immune 0:15:02

CIPO2015: Durable Immune Control of ALL Requires a Multi-Antigen Immune Response

CIPO2015: Genetically Engineered 0:18:38

CIPO2015: Genetically Engineered Macrophages: Overcoming the Brain Tumor Microenvironment

CBSET: Cell Therapies 0:02:06

CBSET: Cell Therapies & Preclinical Collaboration

CIPO2015: Enhancing the 0:20:21

CIPO2015: Enhancing the IQ of CAR T Cells Using the Synthetic Biology Tool Box

CIPO2015: Anti-GD2 mAb 0:32:50

CIPO2015: Anti-GD2 mAb and Next Generation mAb-Based Agents, KIR, Cytokines and Combination Therapy

CIPO2015: NKT Cells 0:14:32

CIPO2015: NKT Cells Selectively Target M2-like Macrophages in Neuroblastoma Tumor Microenvironment

CIPO2015: Clues from 0:31:04

CIPO2015: Clues from Graft-Versus-Host Disease to Design Successful Immunotherapy

CIPO2015: CD19 CAR 0:16:18

CIPO2015: CD19 CAR T Cells During Therapy in Relapsed ALL Pediatric and Young Adult Patients

CIPO2015: Effective Ablation 0:15:49

CIPO2015: Effective Ablation of Chimeric Antigen Receptor-Modified T Cells for AML with Alemtuzumab

CIPO2015: Enhancing Graft 0:13:38

CIPO2015: Enhancing Graft Vs. Tumor Effect Against Neuroblastoma Using an Anti-GD2 Immunocytokine

CIPO2015: Dissecting Tumor 0:31:44

CIPO2015: Dissecting Tumor Heterogeneity with Single-Cell Transcriptomics

Anti-CD22 CAR T-cell 0:01:21

Anti-CD22 CAR T-cell therapy for ALL: trial update, utility for salvage and CD19 status

CIPO2015: Targeting GD2 0:33:10

CIPO2015: Targeting GD2 w/ 3F8 & B7-H3 w/ 8H9: Lessons Learned & Next Generation Therapeutic...

Phase I study 0:03:23

Phase I study of CD22 CAR-T therapy in patients with LBCL who have relapsed after CD19 CAR-T therapy

CD19 CAR T 0:57:03

CD19 CAR T Cell Therapy for Pediatric ALL: The Seattle Children’s Experience

Kuur Therapeutics 0:14:47

Kuur Therapeutics